296 related articles for article (PubMed ID: 34965383)
21. A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development.
Lawrenson K; Fonseca MAS; Liu AY; Segato Dezem F; Lee JM; Lin X; Corona RI; Abbasi F; Vavra KC; Dinh HQ; Gill NK; Seo JH; Coetzee S; Lin YG; Pejovic T; Mhawech-Fauceglia P; Rowat AC; Drapkin R; Karlan BY; Hazelett DJ; Freedman ML; Gayther SA; Noushmehr H
Cell Rep; 2019 Dec; 29(11):3726-3735.e4. PubMed ID: 31825847
[TBL] [Abstract][Full Text] [Related]
22. The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.
Luo LY; Kim E; Cheung HW; Weir BA; Dunn GP; Shen RR; Hahn WC
Mol Cancer Res; 2015 Mar; 13(3):502-9. PubMed ID: 25368431
[TBL] [Abstract][Full Text] [Related]
23. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
24. A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants.
Gusev A; Lawrenson K; Lin X; Lyra PC; Kar S; Vavra KC; Segato F; Fonseca MAS; Lee JM; Pejovic T; Liu G; ; Karlan BY; Freedman ML; Noushmehr H; Monteiro AN; Pharoah PDP; Pasaniuc B; Gayther SA
Nat Genet; 2019 May; 51(5):815-823. PubMed ID: 31043753
[TBL] [Abstract][Full Text] [Related]
25. Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus.
Buckley MA; Woods NT; Tyrer JP; Mendoza-Fandiño G; Lawrenson K; Hazelett DJ; Najafabadi HS; Gjyshi A; Carvalho RS; Lyra PC; Coetzee SG; Shen HC; Yang AW; Earp MA; Yoder SJ; Risch H; Chenevix-Trench G; Ramus SJ; Phelan CM; Coetzee GA; Noushmehr H; Hughes TR; Sellers TA; Goode EL; Pharoah PD; Gayther SA; Monteiro ANA;
Cancer Res; 2019 Feb; 79(3):467-481. PubMed ID: 30487138
[TBL] [Abstract][Full Text] [Related]
26. DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
Cancer Lett; 2021 Mar; 501():224-233. PubMed ID: 33221455
[TBL] [Abstract][Full Text] [Related]
27. Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.
French JD; Johnatty SE; Lu Y; Beesley J; Gao B; Kalimutho M; Henderson MJ; Russell AJ; Kar S; Chen X; Hillman KM; Kaufmann S; Sivakumaran H; O'Reilly M; Wang C; Korbie DJ; ; ; Lambrechts D; Despierre E; Van Nieuwenhuysen E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching PA; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Pisterer J; Hillemanns P; Nakanishi T; Yatabe Y; Goodman MT; Lurie G; Matsuno RK; Thompson PJ; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan JM; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut JM; Iversen E; Weber RP; Brennan D; Berchuck A; Pharoah P; Harnett P; Norris MD; Haber M; Goode EL; Lee JS; Khanna KK; Meyer KB; Chenevix-Trench G; deFazio A; Edwards SL; MacGregor S;
Oncotarget; 2016 Feb; 7(6):6353-68. PubMed ID: 26840454
[TBL] [Abstract][Full Text] [Related]
28. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
Reyes HD; Devor EJ; Warrier A; Newtson AM; Mattson J; Wagner V; Duncan GN; Leslie KK; Gonzalez-Bosquet J
Sci Rep; 2019 Nov; 9(1):17996. PubMed ID: 31784612
[TBL] [Abstract][Full Text] [Related]
29. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
31. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract][Full Text] [Related]
32. Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer.
Auer K; Bachmayr-Heyda A; Aust S; Grunt TW; Pils D
Cancer Lett; 2017 Mar; 388():158-166. PubMed ID: 27940126
[TBL] [Abstract][Full Text] [Related]
33. Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
Lepage CC; Palmer MCL; Farrell AC; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
Br J Cancer; 2021 May; 124(10):1699-1710. PubMed ID: 33731859
[TBL] [Abstract][Full Text] [Related]
34. Combined MEK and BCL-2/X
Iavarone C; Zervantonakis IK; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis UA; Hallberg D; Velculescu VE; Leverson JD; Sampath D; Mills GB; Brugge JS
Mol Cancer Ther; 2019 Mar; 18(3):642-655. PubMed ID: 30679390
[TBL] [Abstract][Full Text] [Related]
35. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
36. NF-κB-miR-155 axis activation mediates ovulation-induced oncogenic effects in fallopian tube epithelium.
Brand H; Barnabas GD; Sapoznik S; Bahar-Shany K; Pozniak Y; Yung Y; Hourvitz A; Geiger T; Jacob-Hirsch J; Levanon K
Carcinogenesis; 2020 Dec; 41(12):1703-1712. PubMed ID: 32614381
[TBL] [Abstract][Full Text] [Related]
37. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
38. HMGA2 and high-grade serous ovarian carcinoma.
Wu J; Wei JJ
J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
[TBL] [Abstract][Full Text] [Related]
39. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
[TBL] [Abstract][Full Text] [Related]
40. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
Liu Z; Gersbach E; Zhang X; Xu X; Dong R; Lee P; Liu J; Kong B; Shao C; Wei JJ
Mol Cancer Res; 2013 Nov; 11(11):1314-25. PubMed ID: 24045973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
